# XLIMus Drug Eluting Stent: a randomIzed Controlled Trial to Assess Endothelization

Study · id `cardio:ct-nct03745053` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03745053](<https://clinicaltrials.gov/study/NCT03745053>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03745053

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

## Technical summary

Registry record NCT03745053. Randomized; single masking; primary purpose treatment. Start 2019-02-05 (actual); primary completion 2023-09-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 180 participants (enrolled count; ClinicalTrials.gov record NCT03745053, source copy `cardio:ctgov-nct03745053-2024-02-07`, retrieved 2026-10-26)
- Started: 2019-02-05 (actual) (ClinicalTrials.gov record NCT03745053, source copy `cardio:ctgov-nct03745053-2024-02-07`, retrieved 2026-10-26)
- Primary completion: 2023-09-02 (actual) (ClinicalTrials.gov record NCT03745053, source copy `cardio:ctgov-nct03745053-2024-02-07`, retrieved 2026-10-26)
- Completion: 2023-09-02 (actual) (ClinicalTrials.gov record NCT03745053, source copy `cardio:ctgov-nct03745053-2024-02-07`, retrieved 2026-10-26)
- Countries: Italy; Spain (ClinicalTrials.gov record NCT03745053, source copy `cardio:ctgov-nct03745053-2024-02-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03745053-2024-02-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: XLIMus Drug Eluting Stent: a randomIzed Controlled Trial to Assess Endothelization
- Acronym: XLIMIT
- Condition: Coronary Artery Disease
- Intervention (Device): Xlimus DES Implantation during coronary angioplasty
- Intervention (Device): Synergy DES Implantation during coronary angioplasty
- Lead sponsor: Cardionovum GmbH
- Lead sponsor class: INDUSTRY
- Collaborator: Mediolanum Cardio Research
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Cardionovum GmbH (`cardio:org-cardionovum-gmbh`)
- Registry lists this organization as a collaborator: Mediolanum Cardio Research (`cardio:org-mediolanum-cardio-research`)

## Provenance

Content hash: 7753bf7084c717af11ec83ff4eed4385b7651e61a5046e50406c706539345224
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
